GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (LTS:0HB0) » Definitions » Cyclically Adjusted Price-to-FCF

Agios Pharmaceuticals (LTS:0HB0) Cyclically Adjusted Price-to-FCF : (As of Jun. 05, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Agios Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Agios Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Agios Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agios Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Agios Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Agios Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Agios Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Agios Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agios Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Agios Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


;
;

Agios Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Agios Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Agios Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-1.954/134.9266*134.9266
=-1.954

Current CPI (Mar. 2025) = 134.9266.

Agios Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.185 100.684 -0.248
201509 -0.750 100.392 -1.008
201512 -0.869 99.792 -1.175
201603 -0.569 100.470 -0.764
201606 4.086 101.688 5.422
201609 -1.361 101.861 -1.803
201612 -1.245 101.863 -1.649
201703 -1.759 102.862 -2.307
201706 -1.284 103.349 -1.676
201709 -1.645 104.136 -2.131
201712 -1.552 104.011 -2.013
201803 -1.803 105.290 -2.311
201806 -1.191 106.317 -1.511
201809 -1.154 106.507 -1.462
201812 -1.293 105.998 -1.646
201903 -1.802 107.251 -2.267
201906 -1.523 108.070 -1.901
201909 -1.490 108.329 -1.856
201912 -1.567 108.420 -1.950
202003 -1.597 108.902 -1.979
202006 -1.043 108.767 -1.294
202009 -1.062 109.815 -1.305
202012 -0.721 109.897 -0.885
202103 -1.751 111.754 -2.114
202106 -1.925 114.631 -2.266
202109 -1.493 115.734 -1.741
202112 -1.632 117.630 -1.872
202203 -1.843 121.301 -2.050
202206 -1.390 125.017 -1.500
202209 -1.302 125.227 -1.403
202212 -1.206 125.222 -1.299
202303 -1.730 127.348 -1.833
202306 -1.200 128.729 -1.258
202309 -1.425 129.860 -1.481
202312 -1.300 129.419 -1.355
202403 -1.774 131.776 -1.816
202406 -1.281 132.554 -1.304
202409 -1.448 133.029 -1.469
202412 -2.281 133.157 -2.311
202503 -1.954 134.927 -1.954

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Agios Pharmaceuticals  (LTS:0HB0) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Agios Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Agios Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Agios Pharmaceuticals Business Description

Traded in Other Exchanges
Address
88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Agios Pharmaceuticals Headlines

No Headlines